Global Antiviral Immunoglobulin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Antiviral Immunoglobulin Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Human Plasma Derived Polyclonal
- 1.3.3 Hyperimmune Specific Globulin
- 1.3.4 Recombinant Monoclonal Antibody (mAb)
- 1.3.5 Animal Derived (Equine/Ovine)
- 1.3.6 Others
- 1.4 Market Analysis by IgG Purity
- 1.4.1 Overview: Global Antiviral Immunoglobulin Consumption Value by IgG Purity: 2021 Versus 2025 Versus 2032
- 1.4.2 Standard Fractionated Grade (90%–95%)
- 1.4.3 Clinical High Purity Grade (96%–98%)
- 1.4.4 Ultra Purified Specialty Grade(99%)
- 1.5 Market Analysis by Therapeutic Area
- 1.5.1 Overview: Global Antiviral Immunoglobulin Consumption Value by Therapeutic Area: 2021 Versus 2025 Versus 2032
- 1.5.2 Transplantation
- 1.5.3 Infectious Disease Prophylaxis
- 1.5.4 Immunodeficiency
- 1.5.5 Neurology (Autoimmune)
- 1.5.6 Others
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Antiviral Immunoglobulin Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospitals
- 1.6.3 Specialty Clinics
- 1.6.4 Home Care
- 1.6.5 Others
- 1.7 Global Antiviral Immunoglobulin Market Size & Forecast
- 1.7.1 Global Antiviral Immunoglobulin Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Antiviral Immunoglobulin Sales Quantity (2021-2032)
- 1.7.3 Global Antiviral Immunoglobulin Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 ADMA Biologics (US)
- 2.1.1 ADMA Biologics (US) Details
- 2.1.2 ADMA Biologics (US) Major Business
- 2.1.3 ADMA Biologics (US) Antiviral Immunoglobulin Product and Services
- 2.1.4 ADMA Biologics (US) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 ADMA Biologics (US) Recent Developments/Updates
- 2.2 AstraZeneca (UK/Sweden)
- 2.2.1 AstraZeneca (UK/Sweden) Details
- 2.2.2 AstraZeneca (UK/Sweden) Major Business
- 2.2.3 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product and Services
- 2.2.4 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 AstraZeneca (UK/Sweden) Recent Developments/Updates
- 2.3 Bharat Serums & Vaccines (India)
- 2.3.1 Bharat Serums & Vaccines (India) Details
- 2.3.2 Bharat Serums & Vaccines (India) Major Business
- 2.3.3 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product and Services
- 2.3.4 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Bharat Serums & Vaccines (India) Recent Developments/Updates
- 2.4 Biotest (Germany)
- 2.4.1 Biotest (Germany) Details
- 2.4.2 Biotest (Germany) Major Business
- 2.4.3 Biotest (Germany) Antiviral Immunoglobulin Product and Services
- 2.4.4 Biotest (Germany) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Biotest (Germany) Recent Developments/Updates
- 2.5 Boya Bio (China)
- 2.5.1 Boya Bio (China) Details
- 2.5.2 Boya Bio (China) Major Business
- 2.5.3 Boya Bio (China) Antiviral Immunoglobulin Product and Services
- 2.5.4 Boya Bio (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Boya Bio (China) Recent Developments/Updates
- 2.6 China Biologic Products (CNBG) (China)
- 2.6.1 China Biologic Products (CNBG) (China) Details
- 2.6.2 China Biologic Products (CNBG) (China) Major Business
- 2.6.3 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product and Services
- 2.6.4 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 China Biologic Products (CNBG) (China) Recent Developments/Updates
- 2.7 CSL Behring (US/Germany)
- 2.7.1 CSL Behring (US/Germany) Details
- 2.7.2 CSL Behring (US/Germany) Major Business
- 2.7.3 CSL Behring (US/Germany) Antiviral Immunoglobulin Product and Services
- 2.7.4 CSL Behring (US/Germany) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 CSL Behring (US/Germany) Recent Developments/Updates
- 2.8 Emergent BioSolutions (US)
- 2.8.1 Emergent BioSolutions (US) Details
- 2.8.2 Emergent BioSolutions (US) Major Business
- 2.8.3 Emergent BioSolutions (US) Antiviral Immunoglobulin Product and Services
- 2.8.4 Emergent BioSolutions (US) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Emergent BioSolutions (US) Recent Developments/Updates
- 2.9 GC Pharma (S. Korea)
- 2.9.1 GC Pharma (S. Korea) Details
- 2.9.2 GC Pharma (S. Korea) Major Business
- 2.9.3 GC Pharma (S. Korea) Antiviral Immunoglobulin Product and Services
- 2.9.4 GC Pharma (S. Korea) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 GC Pharma (S. Korea) Recent Developments/Updates
- 2.10 Grifols (Spain)
- 2.10.1 Grifols (Spain) Details
- 2.10.2 Grifols (Spain) Major Business
- 2.10.3 Grifols (Spain) Antiviral Immunoglobulin Product and Services
- 2.10.4 Grifols (Spain) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Grifols (Spain) Recent Developments/Updates
- 2.11 Hualan Biological (China)
- 2.11.1 Hualan Biological (China) Details
- 2.11.2 Hualan Biological (China) Major Business
- 2.11.3 Hualan Biological (China) Antiviral Immunoglobulin Product and Services
- 2.11.4 Hualan Biological (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Hualan Biological (China) Recent Developments/Updates
- 2.12 Intas Pharmaceuticals (India)
- 2.12.1 Intas Pharmaceuticals (India) Details
- 2.12.2 Intas Pharmaceuticals (India) Major Business
- 2.12.3 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product and Services
- 2.12.4 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Intas Pharmaceuticals (India) Recent Developments/Updates
- 2.13 Kamada (Israel)
- 2.13.1 Kamada (Israel) Details
- 2.13.2 Kamada (Israel) Major Business
- 2.13.3 Kamada (Israel) Antiviral Immunoglobulin Product and Services
- 2.13.4 Kamada (Israel) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 Kamada (Israel) Recent Developments/Updates
- 2.14 Kedrion (Italy)
- 2.14.1 Kedrion (Italy) Details
- 2.14.2 Kedrion (Italy) Major Business
- 2.14.3 Kedrion (Italy) Antiviral Immunoglobulin Product and Services
- 2.14.4 Kedrion (Italy) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Kedrion (Italy) Recent Developments/Updates
- 2.15 LFB Group (France)
- 2.15.1 LFB Group (France) Details
- 2.15.2 LFB Group (France) Major Business
- 2.15.3 LFB Group (France) Antiviral Immunoglobulin Product and Services
- 2.15.4 LFB Group (France) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.15.5 LFB Group (France) Recent Developments/Updates
- 2.16 Octapharma (Switzerland)
- 2.16.1 Octapharma (Switzerland) Details
- 2.16.2 Octapharma (Switzerland) Major Business
- 2.16.3 Octapharma (Switzerland) Antiviral Immunoglobulin Product and Services
- 2.16.4 Octapharma (Switzerland) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.16.5 Octapharma (Switzerland) Recent Developments/Updates
- 2.17 Regeneron (US)
- 2.17.1 Regeneron (US) Details
- 2.17.2 Regeneron (US) Major Business
- 2.17.3 Regeneron (US) Antiviral Immunoglobulin Product and Services
- 2.17.4 Regeneron (US) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.17.5 Regeneron (US) Recent Developments/Updates
- 2.18 Roche (Switzerland)
- 2.18.1 Roche (Switzerland) Details
- 2.18.2 Roche (Switzerland) Major Business
- 2.18.3 Roche (Switzerland) Antiviral Immunoglobulin Product and Services
- 2.18.4 Roche (Switzerland) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.18.5 Roche (Switzerland) Recent Developments/Updates
- 2.19 Sanofi (France)
- 2.19.1 Sanofi (France) Details
- 2.19.2 Sanofi (France) Major Business
- 2.19.3 Sanofi (France) Antiviral Immunoglobulin Product and Services
- 2.19.4 Sanofi (France) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.19.5 Sanofi (France) Recent Developments/Updates
- 2.20 Shanghai RAAS (China)
- 2.20.1 Shanghai RAAS (China) Details
- 2.20.2 Shanghai RAAS (China) Major Business
- 2.20.3 Shanghai RAAS (China) Antiviral Immunoglobulin Product and Services
- 2.20.4 Shanghai RAAS (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.20.5 Shanghai RAAS (China) Recent Developments/Updates
- 2.21 Shuanglin Bio (China)
- 2.21.1 Shuanglin Bio (China) Details
- 2.21.2 Shuanglin Bio (China) Major Business
- 2.21.3 Shuanglin Bio (China) Antiviral Immunoglobulin Product and Services
- 2.21.4 Shuanglin Bio (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.21.5 Shuanglin Bio (China) Recent Developments/Updates
- 2.22 SK Plasma (S. Korea)
- 2.22.1 SK Plasma (S. Korea) Details
- 2.22.2 SK Plasma (S. Korea) Major Business
- 2.22.3 SK Plasma (S. Korea) Antiviral Immunoglobulin Product and Services
- 2.22.4 SK Plasma (S. Korea) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.22.5 SK Plasma (S. Korea) Recent Developments/Updates
- 2.23 Takeda Pharmaceutical (Japan)
- 2.23.1 Takeda Pharmaceutical (Japan) Details
- 2.23.2 Takeda Pharmaceutical (Japan) Major Business
- 2.23.3 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product and Services
- 2.23.4 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.23.5 Takeda Pharmaceutical (Japan) Recent Developments/Updates
- 2.24 Tiantan Bio (China)
- 2.24.1 Tiantan Bio (China) Details
- 2.24.2 Tiantan Bio (China) Major Business
- 2.24.3 Tiantan Bio (China) Antiviral Immunoglobulin Product and Services
- 2.24.4 Tiantan Bio (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.24.5 Tiantan Bio (China) Recent Developments/Updates
- 2.25 Weiguang Biological (China)
- 2.25.1 Weiguang Biological (China) Details
- 2.25.2 Weiguang Biological (China) Major Business
- 2.25.3 Weiguang Biological (China) Antiviral Immunoglobulin Product and Services
- 2.25.4 Weiguang Biological (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.25.5 Weiguang Biological (China) Recent Developments/Updates
- 2.26 Yuanda Shuyang (China)
- 2.26.1 Yuanda Shuyang (China) Details
- 2.26.2 Yuanda Shuyang (China) Major Business
- 2.26.3 Yuanda Shuyang (China) Antiviral Immunoglobulin Product and Services
- 2.26.4 Yuanda Shuyang (China) Antiviral Immunoglobulin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.26.5 Yuanda Shuyang (China) Recent Developments/Updates
3 Competitive Environment: Antiviral Immunoglobulin by Manufacturer
- 3.1 Global Antiviral Immunoglobulin Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Antiviral Immunoglobulin Revenue by Manufacturer (2021-2026)
- 3.3 Global Antiviral Immunoglobulin Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Antiviral Immunoglobulin by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Antiviral Immunoglobulin Manufacturer Market Share in 2025
- 3.4.3 Top 6 Antiviral Immunoglobulin Manufacturer Market Share in 2025
- 3.5 Antiviral Immunoglobulin Market: Overall Company Footprint Analysis
- 3.5.1 Antiviral Immunoglobulin Market: Region Footprint
- 3.5.2 Antiviral Immunoglobulin Market: Company Product Type Footprint
- 3.5.3 Antiviral Immunoglobulin Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Antiviral Immunoglobulin Market Size by Region
- 4.1.1 Global Antiviral Immunoglobulin Sales Quantity by Region (2021-2032)
- 4.1.2 Global Antiviral Immunoglobulin Consumption Value by Region (2021-2032)
- 4.1.3 Global Antiviral Immunoglobulin Average Price by Region (2021-2032)
- 4.2 North America Antiviral Immunoglobulin Consumption Value (2021-2032)
- 4.3 Europe Antiviral Immunoglobulin Consumption Value (2021-2032)
- 4.4 Asia-Pacific Antiviral Immunoglobulin Consumption Value (2021-2032)
- 4.5 South America Antiviral Immunoglobulin Consumption Value (2021-2032)
- 4.6 Middle East & Africa Antiviral Immunoglobulin Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 5.2 Global Antiviral Immunoglobulin Consumption Value by Type (2021-2032)
- 5.3 Global Antiviral Immunoglobulin Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 6.2 Global Antiviral Immunoglobulin Consumption Value by Application (2021-2032)
- 6.3 Global Antiviral Immunoglobulin Average Price by Application (2021-2032)
7 North America
- 7.1 North America Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 7.2 North America Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 7.3 North America Antiviral Immunoglobulin Market Size by Country
- 7.3.1 North America Antiviral Immunoglobulin Sales Quantity by Country (2021-2032)
- 7.3.2 North America Antiviral Immunoglobulin Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 8.2 Europe Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 8.3 Europe Antiviral Immunoglobulin Market Size by Country
- 8.3.1 Europe Antiviral Immunoglobulin Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Antiviral Immunoglobulin Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Antiviral Immunoglobulin Market Size by Region
- 9.3.1 Asia-Pacific Antiviral Immunoglobulin Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Antiviral Immunoglobulin Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 10.2 South America Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 10.3 South America Antiviral Immunoglobulin Market Size by Country
- 10.3.1 South America Antiviral Immunoglobulin Sales Quantity by Country (2021-2032)
- 10.3.2 South America Antiviral Immunoglobulin Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antiviral Immunoglobulin Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Antiviral Immunoglobulin Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Antiviral Immunoglobulin Market Size by Country
- 11.3.1 Middle East & Africa Antiviral Immunoglobulin Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Antiviral Immunoglobulin Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Antiviral Immunoglobulin Market Drivers
- 12.2 Antiviral Immunoglobulin Market Restraints
- 12.3 Antiviral Immunoglobulin Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Antiviral Immunoglobulin and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Antiviral Immunoglobulin
- 13.3 Antiviral Immunoglobulin Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Antiviral Immunoglobulin Typical Distributors
- 14.3 Antiviral Immunoglobulin Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Antiviral Immunoglobulin market size was valued at US$ 11581 million in 2025 and is forecast to a readjusted size of US$ 17924 million by 2032 with a CAGR of 6.4% during review period.
Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.
This report is a detailed and comprehensive analysis for global Antiviral Immunoglobulin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Antiviral Immunoglobulin market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Antiviral Immunoglobulin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Antiviral Immunoglobulin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Antiviral Immunoglobulin market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antiviral Immunoglobulin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antiviral Immunoglobulin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), China Biologic Products (CNBG) (China), CSL Behring (US/Germany), Emergent BioSolutions (US), GC Pharma (S. Korea), Grifols (Spain), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Antiviral Immunoglobulin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Human Plasma Derived Polyclonal
Hyperimmune Specific Globulin
Recombinant Monoclonal Antibody (mAb)
Animal Derived (Equine/Ovine)
Others
Market segment by IgG Purity
Standard Fractionated Grade (90%–95%)
Clinical High Purity Grade (96%–98%)
Ultra Purified Specialty Grade(99%)
Market segment by Therapeutic Area
Transplantation
Infectious Disease Prophylaxis
Immunodeficiency
Neurology (Autoimmune)
Others
Market segment by Application
Hospitals
Specialty Clinics
Home Care
Others
Major players covered
ADMA Biologics (US)
AstraZeneca (UK/Sweden)
Bharat Serums & Vaccines (India)
Biotest (Germany)
Boya Bio (China)
China Biologic Products (CNBG) (China)
CSL Behring (US/Germany)
Emergent BioSolutions (US)
GC Pharma (S. Korea)
Grifols (Spain)
Hualan Biological (China)
Intas Pharmaceuticals (India)
Kamada (Israel)
Kedrion (Italy)
LFB Group (France)
Octapharma (Switzerland)
Regeneron (US)
Roche (Switzerland)
Sanofi (France)
Shanghai RAAS (China)
Shuanglin Bio (China)
SK Plasma (S. Korea)
Takeda Pharmaceutical (Japan)
Tiantan Bio (China)
Weiguang Biological (China)
Yuanda Shuyang (China)
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antiviral Immunoglobulin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antiviral Immunoglobulin, with price, sales quantity, revenue, and global market share of Antiviral Immunoglobulin from 2021 to 2026.
Chapter 3, the Antiviral Immunoglobulin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antiviral Immunoglobulin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Antiviral Immunoglobulin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antiviral Immunoglobulin.
Chapter 14 and 15, to describe Antiviral Immunoglobulin sales channel, distributors, customers, research findings and conclusion.